University Medical Center Mainz, Institute of Medical Biostatistics, Epidemiology and Informatics, 55101, Mainz, Germany.
Department of Obstetrics and Gynecology, University Medical Center Mainz, 55101, Mainz, Germany.
Breast Cancer Res Treat. 2022 Jan;191(1):147-157. doi: 10.1007/s10549-021-06412-3. Epub 2021 Oct 9.
Radiotherapy (RT) was identified as a risk factor for long-term cardiac effects in breast cancer patients treated until the 1990s. However, modern techniques reduce radiation exposure of the heart, but some exposure remains unavoidable. In a retrospective cohort study, we investigated cardiac mortality and morbidity of breast cancer survivors treated with recent RT in Germany.
A total of 11,982 breast cancer patients treated between 1998 and 2008 were included. A mortality follow-up was conducted until 06/2018. In order to assess cardiac morbidity occurring after breast cancer treatment, a questionnaire was sent out in 2014 and 2019. The effect of breast cancer laterality on cardiac mortality and morbidity was investigated as a proxy for radiation exposure. We used Cox Proportional Hazards regression analysis, taking potential confounders into account.
After a median follow-up time of 11.1 years, there was no significant association of tumor laterality with cardiac mortality in irradiated patients (hazard ratio (HR) for left-sided versus right-sided tumor 1.09; 95% confidence interval (CI) 0.85-1.41). Furthermore, tumor laterality was not identified as a significant risk factor for cardiac morbidity (HR = 1.05; 95%CI 0.88-1.25).
Even though RT for left-sided breast cancer on average incurs higher radiation dose to the heart than RT for right-sided tumors, we found no evidence that laterality is a strong risk factor for cardiac disease after contemporary RT. However, larger sample sizes, longer follow-up, detailed information on individual risk factors and heart dose are needed to assess clinically manifest late effects of current cancer therapy.
放疗(RT)被认为是 20 世纪 90 年代以前接受治疗的乳腺癌患者发生长期心脏效应的一个风险因素。然而,现代技术减少了心脏的辐射暴露,但有些暴露仍然不可避免。在一项回顾性队列研究中,我们研究了德国最近接受 RT 治疗的乳腺癌幸存者的心脏死亡率和发病率。
共纳入 11982 例 1998 年至 2008 年间接受治疗的乳腺癌患者。进行了死亡率随访,直至 2018 年 6 月。为了评估乳腺癌治疗后发生的心脏发病率,我们于 2014 年和 2019 年发送了一份调查问卷。通过研究乳腺癌侧别的差异来评估心脏死亡率和发病率,这可以作为辐射暴露的替代指标。我们使用 Cox 比例风险回归分析,考虑了潜在的混杂因素。
在中位随访时间为 11.1 年后,在接受放疗的患者中,肿瘤侧别与心脏死亡率之间没有显著关联(左侧肿瘤与右侧肿瘤的危险比(HR)为 1.09;95%置信区间(CI)为 0.85-1.41)。此外,肿瘤侧别也不是心脏发病率的显著危险因素(HR=1.05;95%CI 0.88-1.25)。
尽管左侧乳腺癌放疗平均对心脏的辐射剂量高于右侧肿瘤放疗,但我们没有证据表明侧别是当代 RT 后发生心脏疾病的一个强危险因素。然而,需要更大的样本量、更长的随访时间、详细的个体危险因素和心脏剂量信息来评估当前癌症治疗的临床明显晚期效应。